Crizotinib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uveal Melanoma
Conditions
Uveal Melanoma
Trial Timeline
Mar 1, 2015 → Jul 3, 2019
NCT ID
NCT02223819About Crizotinib
Crizotinib is a phase 2 stage product being developed by Pfizer for Uveal Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02223819. Target conditions include Uveal Melanoma.
What happened to similar drugs?
0 of 2 similar drugs in Uveal Melanoma were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03085186 | Pre-clinical | Completed |
| NCT02473497 | Pre-clinical | Completed |
| NCT02824094 | Pre-clinical | Completed |
| NCT05160922 | Approved | Active |
| NCT04084717 | Phase 2 | Recruiting |
| NCT03672643 | Approved | Terminated |
| NCT03088930 | Phase 2 | Completed |
| NCT03375242 | Pre-clinical | Recruiting |
| NCT02612194 | Phase 2 | Terminated |
| NCT02679170 | Pre-clinical | Completed |
| NCT02223819 | Phase 2 | Completed |
| NCT02270034 | Phase 1 | Completed |
| NCT01500824 | Phase 2 | Withdrawn |
| NCT02183870 | Phase 2 | Completed |
| NCT01945021 | Phase 2 | Completed |
| NCT02034981 | Phase 2 | Completed |
| NCT01121588 | Phase 1 | Terminated |
| NCT01297595 | Phase 1 | Completed |
| NCT01154218 | Phase 1 | Completed |
| NCT01125904 | Phase 1 | Completed |
Competing Products
20 competing products in Uveal Melanoma